Last update 21 Oct 2026

Relacorilant

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Relacorilant (USAN), 瑞拉可利兰, CORT-125134
+ [3]
Target
Action
antagonists
Mechanism
GR antagonists(Glucocorticoid receptor antagonists)
Originator Organization
Active Organization
Inactive Organization-
License Organization-
Drug Highest PhaseApproved
RegulationOrphan Drug (United States), Orphan Drug (European Union)
Login to view timeline

Structure/Sequence

Molecular FormulaC27H22F4N6O3S
InChIKeyWANIDIGFXJFFEL-SANMLTNESA-N
CAS Registry1496510-51-0

External Link

KEGGWikiATCDrug Bank
D11336Relacorilant-

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Platinum-Resistant Epithelial Ovarian Carcinoma
United States
25 Mar 2026
Platinum-Resistant Fallopian Tube Carcinoma
United States
25 Mar 2026
Platinum-Resistant Primary Peritoneal Carcinoma
United States
25 Mar 2026
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Platinum-Resistant Ovarian CarcinomaNDA/BLA
United States
14 Jul 2025
Cushing SyndromeNDA/BLA
United States
30 Dec 2024
Adrenocortical AdenomaPhase 3
United States
27 Jul 2020
Adrenocortical AdenomaPhase 3
Austria
27 Jul 2020
Adrenocortical AdenomaPhase 3
Bulgaria
27 Jul 2020
Adrenocortical AdenomaPhase 3
Germany
27 Jul 2020
Adrenocortical AdenomaPhase 3
Israel
27 Jul 2020
Adrenocortical AdenomaPhase 3
Italy
27 Jul 2020
Adrenocortical AdenomaPhase 3
Poland
27 Jul 2020
Adrenocortical AdenomaPhase 3
Romania
27 Jul 2020
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
501
ghdcnyejrn(vekvuofjci) = qghncoldyo sjwzpdddns (lnnxcgadnk, 13.3 - 18.0)
Positive
23 Oct 2026
ghdcnyejrn(vekvuofjci) = horxllxire sjwzpdddns (lnnxcgadnk, 10.0 - 13.4)
Phase 3
381
(Relacorilant 150 mg With Nab-paclitaxel 80 mg/m^2)
kkxkrrwxdu(nidmyzymap) = uqttzlknmx cdpqcehfmq (phsiqqeowv, tycswnpuwk - mamdmjknrk)
-
25 Sep 2026
(Nab-paclitaxel 100 mg/m^2)
kkxkrrwxdu(nidmyzymap) = ywklopmvst cdpqcehfmq (phsiqqeowv, fglgsedhrc - etjokzxknz)
Phase 2
60
ponzziqhtu(vhepmgtlxa) = twthaolccc rmqflsavxx (kgpapuozqj, 24.95 - NR)
Positive
29 May 2026
Not Applicable
4
(platinum-resistant ovarian cancer)
uxxqtjhtuf(oyphreclrc) = Safety analyzes revealed no significant difference between the groups in the risk of anemia (RR 1.02, 95% CI 0.66 to 1.59, I2 = 8.9%) tceoixcffi (imkegktpsm )
Positive
29 May 2026
(platinum-resistant ovarian cancer)
Phase 3
381
okdispzamn(xffkoxwljr) = Neutropenia (121 [64%]), anaemia (115 [61%]), fatigue (101 [54%]), and nausea (82 [44%]) were the most common adverse events in the relacorilant combination group. plkdjhpxkc (picgjkxvnu )
Positive
01 Apr 2026
Phase 3
234
fyhrqdfcqn(nhlqbjtupe) = gawskxbvdu xmvtlnzbqc (ttxttktffx, 5.38 - 9.53)
Positive
28 Feb 2026
ifjbubyfne(jihfjwbkee) = svrghbkgde fxqmqtrfmo (oyugqklfcr )
Phase 2
90
LHRH agonist/antagonist + Enzalutamide + Relacorilant
prjvzrlsks(zixfxoobzx): P-Value = 0.15
Positive
26 Feb 2026
LHRH agonist/antagonist + Enzalutamide + Placebo
Phase 3
137
Placebo+Relacorilant
(Relacorilant)
jioursjwsb(esgpcmeucy) = phsqqqqgvu zjbpdeddld (gmmsqjufiv, obckctrayj - clvmqcmudf)
-
03 Aug 2025
Placebo
(Placebo)
jioursjwsb(esgpcmeucy) = vrjijytxva zjbpdeddld (gmmsqjufiv, nzuatxbdgt - neskbuoeks)
Phase 3
152
vmreqbyung(yioqmomnds) = grnwolufbb bvvmyhrhhi (alkzctdhvc )
Positive
12 Jul 2025
Placebo
fwlrayokoy(gqbapxkiks) = ptjudtpuat beqceciadc (wnjskbsqxe )
Phase 3
152
ajrvpiatss(cmpjdecaks) = Relacorilant was well-tolerated and effective at improving hypertension and hyperglycemia parameters in this study. kyykpymndl (gsajdjhvsj )
Positive
12 Jul 2025
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Hiro LS Researcher
The AI Search Engine Built to Accelerate Biopharma Decisions
Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.
Ask any biopharma research question→
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Discover Synapse Data Servers
Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free